| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 | 6,622 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 | 4,485 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 | 2,137 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % | 31 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 | 400 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 | 1,521 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 |
Zydus Life Science
Zydus Life Science
1,002.90
+1.65
(0.16%)
Key Fundamentals
Market Cap
1,00,749.20 Cr
EPS
44.97
PE Ratio
21.39
Dividend Yield
1.10 %
Industry
Healthcare 52 Week High
1,059.05
52 Week Low
795.00
PB Ratio
4.21
Debt to Equity
0.09
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from25 analysts
Actual
Company News
View All News
Zydus Lifesciences has received approval from the US Food and Drug Administration for its Baddi manufacturing plant. The approval has been labeled as a voluntary action indicated.
Zydus Life Schedules Q2 Financial Performance Review for November 6Today
Zydus Life has announced it will review its Q2 financial performance on November 6. The company has set this date for examining its quarterly results.
Zydus Lifesciences has completed its acquisition of French company Amplitude Surgical SA through its wholly owned subsidiary Zydus MedTech France SAS. The subsidiary acquired the remaining 14.4% share capital and voting rights on October 24, 2025, through mandatory tender offer and squeeze-out, bringing its total ownership to 100%. Zydus MedTech France had previously acquired 85.6% of Amplitude Surgical's share capital and voting rights in July 2025. The transaction was consummated on October 24, 2025, making Amplitude Surgical a wholly owned subsidiary of Zydus MedTech France.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,715.90 | #1 4,04,767.80 | 38.94 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 67.74 | |
6,512.00 | 1,70,921.90 | 74.05 | 9,712.00 | 18.67 | 2,191 | 26.74 | 60.77 | |
1,581.10 | 1,26,663.90 | 23.55 | 28,409.50 | 7.12 | 5,291 | 9.88 | 52.88 | |
3,599.30 | 1,21,045.00 | 60.48 | 11,539.40 | 6.99 | 1,911 | 19.91 | 54.44 | |
1,250.90 | 1,07,615.10 | #1 18.77 | 33,741.20 | 16.73 | 5,725 | -0.38 | 45.01 | |
1,002.90 | #6 1,00,749.20 | #3 21.39 | #5 23,511.00 | #3 18.55 | #4 4,615 | #6 2.60 | 51.23 | |
2,443.70 | 99,330.30 | 51.89 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.93 | |
1,955.90 | 87,637.50 | 23.57 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 51.72 | |
5,535.00 | 64,947.70 | 27.84 | 13,458.30 | 3.70 | 2,216 | 21.39 | 55.26 | |
1,111.70 | 63,853.30 | 19.01 | 32,345.60 | 9.43 | 3,484 | -10.24 | 55.31 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
112.02 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 | 13,134 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 | 17,046 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 | 14,968 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 | 9,042 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 | 1,802 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 | 26,358 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 | 414 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,377 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,196 | 6,777 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,779 | 2,014 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % | 74.99 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % | 7.13 % | 7.34 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % | 11.13 % | 10.86 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % | 5.46 % | 5.49 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % | 1.28 % | 1.32 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 1.1 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jul 2021 |  Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 26 Jul 2024 | Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 25 Jul 2025 | Dividend | ₹ 11.00 /share | 25 Jul 2025 | 902.70 | 971.05 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 969.80 | 955.50 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 955.50 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 hours ago
3 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 hours ago
3 hours agoBoard Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30 2025.9 hours ago
9 hours agoAnnouncement under Regulation 30 (LODR)-Updates on Acquisition3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoUpdateOct 17, 2025
Oct 17, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 09, 2025
Oct 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 06, 2025
Oct 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 04, 2025
Oct 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 01, 2025
Oct 01, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 27, 2025
Sep 27, 2025Receipt Of Order From Commissioner Of CGST AhmedabadSep 25, 2025
Sep 25, 2025Transcript Of The 30Th Annual General MeetingSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 23, 2025
Sep 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 21, 2025
Sep 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 16, 2025
Sep 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 15, 2025
Sep 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 04, 2025
Sep 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 02, 2025
Sep 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 26, 2025
Aug 26, 2025Intimation Of ESG RatingAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 20, 2025
Aug 20, 2025UpdateAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 12, 2025
Aug 12, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 12, 2025
Aug 12, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Aug 12, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Aug 12, 2025Unaudited Financial Results For The Quarter Ended On June 30 2025Aug 12, 2025
Aug 12, 2025Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30 2025Aug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Aug 04, 2025
Aug 04, 2025Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 01, 2025
Aug 01, 2025Mutual Fund Holdings
Nippon India Pharma Fund Direct-Growth 
ICICI Prudential Value Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Edelweiss Balanced Advantage Fund Direct-Growth 
Parag Parikh Flexi Cap Fund Direct-Growth 
Sundaram Mid Cap Fund Direct-Growth 
DSP Quant Fund Direct - Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
HDFC Multi Cap Fund Direct - Growth 
Mirae Asset Arbitrage Fund Direct - Growth 
Bandhan Arbitrage Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Baroda BNP Paribas Business Conglomerates Fund Direct-Growth 
SBI Arbitrage Opportunities Fund Direct-Growth 
UTI Nifty Next 50 Index Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 50.49
ATR(14)
Volatile 18.47
STOCH(9,6)
Neutral 73.48
STOCH RSI(14)
Overbought 83.01
MACD(12,26)
Bullish 2.40
ADX(14)
Weak Trend 17.78
UO(9)
Bearish 51.31
ROC(12)
Uptrend And Accelerating 0.68
WillR(14)
Neutral -37.32
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years,
2 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
